KRT19 and adenocarcinoma: In the 0.6 μM DMBA-treated group, low-grade adenocarcinomas, containing luminal CK18/CK19-positive or basal/myoepithelial CK14/αSMA-positive cells, developed after injection of the organoids into the nude mouse subcutis.